Catalysts · SNY · CIK 1121404 · page 2 of 3

SNY catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on SNY PDUFA dates and upcoming catalysts. This page continues the list.

Upcoming catalysts (continued)

DateDrugCompanyEventIndicationStatusSource
Sep to Dec 2027Quarter disclosedSAR445399SNYTopline readoutHidradenitis SuppurativaScheduledClinicalTrials.gov
September 2027Month disclosedpcv21 vaccine (PCV21)SNYPrimary completionPneumococcal ImmunizationScheduledClinicalTrials.gov
September 2027Month disclosedSAR445399SNYPrimary completionHidradenitis SuppurativaScheduledClinicalTrials.gov
September 2027Month disclosedamlitelimab (SAR445229)SNYPrimary completionDermatitis AtopicScheduledClinicalTrials.gov
Oct 2027 to Jan 2028Quarter disclosedDupixent (dupilumab)SNYTopline readoutPrurigo NodularisScheduledClinicalTrials.gov
Oct 2027 to Jan 2028Quarter disclosedpcv21 vaccine (PCV21)SNYTopline readoutPneumococcal ImmunizationScheduledClinicalTrials.gov
October 2027Month disclosedpcv21 vaccine (PCV21)SNYPrimary completionPneumococcal ImmunizationScheduledClinicalTrials.gov
October 2027Month disclosedDupixent (dupilumab)SNYPrimary completionPrurigo NodularisScheduledClinicalTrials.gov
October 2027Month disclosedSAR445399SNYPrimary completionNon-cystic Fibrosis BronchiectasisDelayedClinicalTrials.gov
Nov 2027 to Feb 2028Quarter disclosedWayrilz (rilzabrutinib)SNYTopline readoutImmune ThrombocytopeniaScheduledClinicalTrials.gov
November 2027Month disclosedWayrilz (rilzabrutinib)SNYPrimary completionImmune ThrombocytopeniaScheduledClinicalTrials.gov
Dec 2027 to Mar 2028Quarter disclosediiv-hd (standalone)SNYTopline readoutImmunization; Healthy Volunteers; COVID-19 ImmunizationScheduledClinicalTrials.gov
December 2027Month disclosediiv-hd (standalone)SNYPrimary completionImmunization; Healthy Volunteers; COVID-19 ImmunizationScheduledClinicalTrials.gov
March 2028Month disclosedsarilumab sar153191 (regn88) (SAR153191)SNYPrimary completionJuvenile Idiopathic ArthritisScheduledClinicalTrials.gov
Mar to Jun 2028Quarter disclosedsarilumab sar153191 (regn88) (SAR153191)SNYTopline readoutJuvenile Idiopathic ArthritisScheduledClinicalTrials.gov
Mar to Jun 2028Quarter disclosedfrexalimab (SAR441344)SNYTopline readoutMultiple SclerosisScheduledClinicalTrials.gov
Mar to Jun 2028Quarter disclosedTZIELD® (teplizumab)SNYTopline readoutType 1 Diabetes MellitusScheduledClinicalTrials.gov
Mar to Jun 2028Quarter disclosedmenquadfi® (meningococcal polysaccharide [serogroups a, c, w, and y] tetanus toxoid conjugate vaccine) (sanofi pasteur inc., swiftwater, pa, usa)SNYTopline readoutMeningococcal Infection; Healthy VolunteersScheduledClinicalTrials.gov
March 2028Month disclosedTZIELD® (teplizumab)SNYPrimary completionType 1 Diabetes MellitusScheduledClinicalTrials.gov
March 2028Month disclosedmenquadfi® (meningococcal polysaccharide [serogroups a, c, w, and y] tetanus toxoid conjugate vaccine) (sanofi pasteur inc., swiftwater, pa, usa)SNYPrimary completionMeningococcal Infection; Healthy VolunteersScheduledClinicalTrials.gov
March 2028Month disclosedfrexalimab (SAR441344)SNYPrimary completionMultiple SclerosisScheduledClinicalTrials.gov
May to Aug 2028Quarter disclosedWayrilz (rilzabrutinib)SNYTopline readoutAutoimmune Haemolytic AnaemiaScheduledClinicalTrials.gov
May to Aug 2028Quarter disclosedduvakitug (TEV-48574)SNYTopline readoutUlcerative ColitisScheduledClinicalTrials.gov
May to Aug 2028Quarter discloseddupilumab coformulated with berahyaluronidase alfaSNYTopline readoutDermatitis AtopicScheduledClinicalTrials.gov
May 2028Month discloseddupilumab coformulated with berahyaluronidase alfaSNYPrimary completionDermatitis AtopicScheduledClinicalTrials.gov
May 2028Month disclosedduvakitug (TEV-48574)SNYPrimary completionUlcerative ColitisScheduledClinicalTrials.gov
May 2028Month disclosedWayrilz (rilzabrutinib)SNYPrimary completionAutoimmune Haemolytic AnaemiaScheduledClinicalTrials.gov
Jun to Sep 2028Quarter disclosedSAR447537SNYTopline readoutAlpha 1-Antitrypsin Deficiency; EmphysemaScheduledClinicalTrials.gov
Jun to Sep 2028Quarter disclosedTZIELD® (teplizumab)SNYTopline readoutType 1 Diabetes MellitusScheduledClinicalTrials.gov
Jun to Sep 2028Quarter disclosedWayrilz (rilzabrutinib)SNYTopline readoutImmunoglobulin G4 Related DiseaseScheduledClinicalTrials.gov
Jun to Sep 2028Quarter disclosedduvakitug (TEV-48574)SNYTopline readoutHidradenitisScheduledClinicalTrials.gov
June 2028Month disclosedTZIELD® (teplizumab)SNYPrimary completionType 1 Diabetes MellitusScheduledClinicalTrials.gov
June 2028Month disclosedduvakitug (TEV-48574)SNYPrimary completionHidradenitisScheduledClinicalTrials.gov
June 2028Month disclosedWayrilz (rilzabrutinib)SNYPrimary completionImmunoglobulin G4 Related DiseaseScheduledClinicalTrials.gov
June 2028Month disclosedSAR447537SNYPrimary completionAlpha 1-Antitrypsin Deficiency; EmphysemaScheduledClinicalTrials.gov
Jul to Oct 2028Quarter disclosedacne mrna (messenger ribonucleic acid) vaccineSNYTopline readoutAcneScheduledClinicalTrials.gov
Jul to Oct 2028Quarter disclosedbivalent rsv+hmpv protein vaccine (RPF08203)SNYTopline readoutRespiratory Syncytial Virus; Human Metapneumovirus; Healthy VolunteersScheduledClinicalTrials.gov
July 2028Month disclosedbivalent rsv+hmpv protein vaccine (RPF08203)SNYPrimary completionRespiratory Syncytial Virus; Human Metapneumovirus; Healthy VolunteersScheduledClinicalTrials.gov
July 2028Month disclosedacne mrna (messenger ribonucleic acid) vaccineSNYPrimary completionAcneScheduledClinicalTrials.gov
Aug to Nov 2028Quarter disclosedSAR445877SNYTopline readoutGastric Cancer; Oesophageal CarcinomaScheduledClinicalTrials.gov
August 2028Month disclosedSAR445877SNYPrimary completionGastric Cancer; Oesophageal CarcinomaScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedbelumosudil (SAR445761)SNYTopline readoutChronic Graft Versus Host DiseaseScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedbelumosudil (SAR445761)SNYTopline readoutChronic Graft Versus Host DiseaseScheduledClinicalTrials.gov
Sep to Dec 2028Quarter disclosedduvakitug (TEV-48574)SNYTopline readoutUlcerative ColitisScheduledClinicalTrials.gov
September 2028Month disclosedduvakitug (TEV-48574)SNYPrimary completionUlcerative ColitisScheduledClinicalTrials.gov
September 2028Month disclosedbelumosudil (SAR445761)SNYPrimary completionChronic Graft Versus Host DiseaseScheduledClinicalTrials.gov
September 2028Month disclosedbelumosudil (SAR445761)SNYPrimary completionChronic Graft Versus Host DiseaseScheduledClinicalTrials.gov
Nov 2028 to Feb 2029Quarter disclosedisatuximab intravenous (iv)SNYTopline readoutPlasma Cell MyelomaScheduledClinicalTrials.gov
November 2028Month disclosedisatuximab intravenous (iv)SNYPrimary completionPlasma Cell MyelomaScheduledClinicalTrials.gov
Dec 2028 to Mar 2029Quarter disclosedDupixent (dupilumab)SNYTopline readoutWheezing; AsthmaScheduledClinicalTrials.gov
December 2028Month disclosedDupixent (dupilumab)SNYPrimary completionWheezing; AsthmaScheduledClinicalTrials.gov
Jan to Apr 2029Quarter disclosedamlitelimab (SAR445229)SNYTopline readoutDermatitis AtopicScheduledClinicalTrials.gov
Jan to Apr 2029Quarter disclosedbelumosudil (SAR445761)SNYTopline readoutLung Transplant RejectionScheduledClinicalTrials.gov
January 2029Month disclosedamlitelimab (SAR445229)SNYPrimary completionDermatitis AtopicScheduledClinicalTrials.gov
January 2029Month disclosedbelumosudil (SAR445761)SNYPrimary completionLung Transplant RejectionScheduledClinicalTrials.gov
Feb to May 2029Quarter disclosedlunsekimig (SAR443765)SNYTopline readoutChronic Rhinosinusitis With Nasal PolypsScheduledClinicalTrials.gov
February 2029Month disclosedlunsekimig (SAR443765)SNYPrimary completionChronic Rhinosinusitis With Nasal PolypsScheduledClinicalTrials.gov
Apr to Jul 2029Quarter disclosedtolebrutinib (SAR442168)SNYTopline readout—ScheduledClinicalTrials.gov
April 2029Month disclosedtolebrutinib (SAR442168)SNYPrimary completion—ScheduledClinicalTrials.gov
May to Aug 2029Quarter disclosedduvakitug (TEV-48574)SNYTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
May 2029Month disclosedduvakitug (TEV-48574)SNYPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
Jun to Sep 2029Quarter disclosedKevzara (sarilumab)SNYTopline readoutPolymyalgia RheumaticaScheduledClinicalTrials.gov
June 2029Month disclosedKevzara (sarilumab)SNYPrimary completionPolymyalgia RheumaticaScheduledClinicalTrials.gov
Jul to Oct 2029Quarter disclosedSAR448851SNYTopline readoutDementia, Alzheimer's Type; Alzheimer's DiseaseScheduledClinicalTrials.gov
July 2029Month disclosedSAR448851SNYPrimary completionDementia, Alzheimer's Type; Alzheimer's DiseaseScheduledClinicalTrials.gov
Aug to Nov 2029Quarter disclosedduvakitug (TEV-48574)SNYTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
Aug to Nov 2029Quarter disclosedQfitlia™ (fitusiran)SNYTopline readoutHemophiliaScheduledClinicalTrials.gov
Aug to Nov 2029Quarter disclosedfrexalimab (SAR441344)SNYTopline readoutKidney Transplant RejectionScheduledClinicalTrials.gov
August 2029Month disclosedQfitlia™ (fitusiran)SNYPrimary completionHemophiliaScheduledClinicalTrials.gov
August 2029Month disclosedduvakitug (TEV-48574)SNYPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
August 2029Month disclosedfrexalimab (SAR441344)SNYPrimary completionKidney Transplant RejectionScheduledClinicalTrials.gov
Sep to Dec 2029Quarter disclosedbelumosudil (SAR445761)SNYTopline readoutChronic Graft Versus Host DiseaseScheduledClinicalTrials.gov
September 2029Month disclosedbelumosudil (SAR445761)SNYPrimary completionChronic Graft Versus Host DiseaseScheduledClinicalTrials.gov
Oct 2029 to Jan 2030Quarter disclosedriliprubart prefilled pen (pfp) (SAR445088)SNYTopline readoutPolyneuropathy, Inflammatory Demyelinating, ChronicScheduledClinicalTrials.gov
October 2029Month disclosedriliprubart prefilled pen (pfp) (SAR445088)SNYPrimary completionPolyneuropathy, Inflammatory Demyelinating, ChronicScheduledClinicalTrials.gov
Nov 2029 to Feb 2030Quarter disclosedlunsekimig (SAR443765)SNYTopline readoutChronic Obstructive Pulmonary DiseaseScheduledClinicalTrials.gov
Nov 2029 to Feb 2030Quarter disclosedlunsekimig (SAR443765)SNYTopline readoutChronic Obstructive Pulmonary DiseaseScheduledClinicalTrials.gov
November 2029Month disclosedlunsekimig (SAR443765)SNYPrimary completionChronic Obstructive Pulmonary DiseaseScheduledClinicalTrials.gov
November 2029Month disclosedlunsekimig (SAR443765)SNYPrimary completionChronic Obstructive Pulmonary DiseaseScheduledClinicalTrials.gov
Jan to Apr 2030Quarter disclosedCerezyme (imiglucerase)SNYTopline readoutGaucher's Disease Type IIIScheduledClinicalTrials.gov
January 2030Month disclosedCerezyme (imiglucerase)SNYPrimary completionGaucher's Disease Type IIIScheduledClinicalTrials.gov
Oct 2030 to Jan 2031Quarter disclosedisatuximab sar650984 (SAR650984)SNYTopline readoutPlasma Cell MyelomaScheduledClinicalTrials.gov
October 2030Month disclosedisatuximab sar650984 (SAR650984)SNYPrimary completionPlasma Cell MyelomaScheduledClinicalTrials.gov

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
February 12, 2026lunsekimig (SAR443765)SNYPrimary completionDermatitis AtopicCompletedClinicalTrials.gov
February 10, 2026SAR443122SNYPrimary completionColitis UlcerativeCompletedClinicalTrials.gov
January 29, 2026lunsekimig (SAR443765)SNYPrimary completionChronic Rhinosinusitis With Nasal PolypsCompletedClinicalTrials.gov
January 20, 2026yellow fever vaccine (live)SNYPrimary completionYellow Fever ImmunizationCompletedClinicalTrials.gov
January 13, 2026—SNYPDUFA date—ScheduledSEC 8-K Exhibit 99.1
January 12, 2026nvx-cov2705SNYPrimary completionCOVID-19; SARS-CoV-2 InfectionCompletedClinicalTrials.gov
January 12, 2026Cerezyme (imiglucerase)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
December 28, 2025tolebrutinib (SAR442168)SNYPDUFA date—CRL issuedSEC 8-K Exhibit 99.1
December 26, 2025eliglustat gz385660 (GZ385660)SNYPrimary completionGaucher's Disease Type I; Gaucher's Disease Type IIICompletedClinicalTrials.gov
December 25, 2025yellow fever vaccine (live)SNYPrimary completionYellow FeverCompletedClinicalTrials.gov
December 23, 2025tolebrutinib (SAR442168)SNYComplete Response Letter—CRL issuedFDA Complete Response Letters
December 22, 2025SARCLISA® (isatuximab)SNYPrimary completionRelapsed/Refractory Multiple MyelomaCompletedClinicalTrials.gov
December 17, 2025venglustat (gz402671) (GZ402671)SNYPrimary completionFabry DiseaseCompletedClinicalTrials.gov
December 4, 2025rsvt vaccineSNYPrimary completionRSV ImmunisationWithdrawnClinicalTrials.gov
November 25, 2025amlitelimab (SAR445229)SNYPrimary completionDermatitis AtopicCompletedClinicalTrials.gov
November 15, 2025meningococcal polysaccharide (serogroups a, c, y, and w) tetanus toxoid conjugate vaccineSNYPrimary completionMeningococcal Immunisation; Healthy VolunteersCompletedClinicalTrials.gov
November 14, 2025menacyw conjugate vaccineSNYPrimary completionMeningococcal Immunisation; Healthy VolunteersCompletedClinicalTrials.gov
Every catalyst is quoted from SNY’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.